Kalvista Pharmaceuticals, Inc. (NASDAQ: KALV) has appointed Laurence Reid, Ph.D., to its board of directors, effective immediately. Dr. Reid's appointment brings more than three decades of experience in high-growth biotech companies to the company's leadership team. Ben Palleiko, the Chief Executive Officer of Kalvista, expressed his pleasure in welcoming Dr. Reid to the board, citing his extensive biopharmaceutical and strategic experience as a valuable asset for the company.
Dr. Reid's previous experience includes serving as the CEO of Decibel Therapeutics prior to its acquisition by Regeneron Pharmaceuticals in September 2023. He also held the position of an entrepreneur in residence at Third Rock Ventures and served as the Chief Executive Officer of Warp Drive Bio, a small molecule company focused on novel oncology and antibiotic drug discovery based on natural products.
Kalvista Pharmaceuticals is currently awaiting regulatory review by the FDA with a PDUFA goal date of June 17, 2025, for its novel, investigational candidate, Sebetralstat, designed for the oral, on-demand treatment of hereditary angioedema. Additionally, the company has completed Marketing Authorization Application (MAA) submissions for Sebetralstat to the European Medicines Agency and several other countries, including the United Kingdom, Switzerland, Australia, and Singapore. The market has reacted to these announcements by moving the company's shares -0.9% to a price of $9.98. If you want to know more, read the company's complete 8-K report here.
